Regorafenib treatment
HFSR
ADVERSE EVENT, HAND-FOOT SYNDROME
Twenty-seven patients received regorafenib, and six patients completed the study during the 12-week observation period. In addition, 22 patients (82%) required treatment interruption, and four patients (15%) required a dosage reduction (see Table 
Safety dataAbbreviations: AE, adverse event; HFSR, hand-foot syndrome